CME

A C C R E D I T A T I O N
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Tulane University Health Sciences Center and CADRE. Tulane University Health Sciences Center is accredited by the ACCME to provide continuing medical education for physicians.

D E S I G N AT I O N
Tulane University Health Sciences Center designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Tulane University Health Sciences Center presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected because of their recognized expertise.

E D U CAT I O N A L   G R A N T
This educational activity is supported by an unrestricted educational grant from Pfizer Inc.

P R O G R A M   D E S C R I P T I O N
The FDA’s approval of the first noninvasive insulin formulation is another important event in the history of insulin therapy. This program reviews the history and the body of evidence that supports insulin as the most fully tested and most reliably effective treatment for diabetes. It covers the evolution of increasingly sophisticated formulations of insulin, development of various regimens for clinical use, and some of the barriers and controversies that still limit the use of insulin therapy. The potential for inhaled insulin as a catalyst for further improvement of insulin therapy will be reviewed.

E D U CAT I O N A L  O B J E C T I V E S
After viewing this webcast, the participant should be better able to

• Describe historical concepts in insulin therapy
• Assess the potential of insulin as an early and long-term therapy for diabetes
• Develop individualized strategies for reducing A1C values with basal bolus therapy

TA R G E T  A U D I E N C E
Physicians, diabetes educators, and other health care professionals who treat patients with type 2 diabetes will find this webcast valuable.

F A C U L T Y
Moderator
Matthew C. Riddle, MD
Professor of Medicine
Division of Endocrinology, Diabetes, and Clinical Nutrition
Oregon Health & Science University
Portland, Oregon

Faculty Presenters
Lawrence Blonde, MD
Director, Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes, and Metabolic Diseases
Associate Internal Medicine Residency Program Director
Ochsner Clinic Foundation
New Orleans, Louisiana

William T. Cefalu, MD
Chief, Division of Nutrition and Chronic Diseases
Pennington Biomedical Research Center
Louisiana State University System
Baton Rouge, Louisiana

Derek LeRoith, MD, PhD
Chief, Division of Endocrinology, Diabetes, and Bone Diseases
Mount Sinai School of Medicine
New York, New York

D I S C L O S U R E
It is the policy of the Center for Continuing Education at Tulane University Health Sciences Center to plan and implement all of its educational activities in accordance with the ACCME’s Essential Areas and policies to ensure balance, independence, objectivity, and scientific rigor. In accordance with the ACCME’s 2004 Standards for Commercial Support, everyone who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all relevant financial relationships with any commercial interests within the past 12 months that create a real or apparent conflict of interest. Individuals who do not disclose are disqualified from participating in a CME activity. Individuals with potential for influence or control of CME content include planners and planning committee members, authors, teachers, educational activity directors, educational partners, and others who participate, eg, facilitators and moderators. This disclosure pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be resolved prior to the educational activity. Disclosure of off-label, experimental, or investigational use of drugs or devices must also be made known to the audience.

F A C U L T Y  D I S C L O S U R E

Matthew Riddle, MD
Grant/Research Support:	Amylin Pharmaceuticals, Inc., Lilly ICOS LLC, sanofi-aventis
Consultant:	Amylin Pharmaceuticals, Inc., Lilly ICOS LLC, Novo Nordisk Pharmaceuticals, Inc., sanofi-aventis
Speakers' Bureau:	Pfizer Inc
Lawrence Blonde, MD
Grants/Research Support:	Amylin Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, MannKind Corporation, Merck & Co., Inc., Novartis, Novo Nordisk Pharmaceuticals, Inc., Pfizer Inc, sanofi-aventis
Consultant/Advisory Board:	KOS Pharmaceuticals, US Surgical
Speakers' Bureau:	Abbott Laboratories, Amylin Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline, LifeScan, Inc., Merck & Co., Inc., Novartis, Novo Nordisk Pharmaceuticals, Inc., Pfizer Inc, sanofi-aventis
Dr Blonde has also disclosed that his spouse is a shareholder of Amylin Pharmaceuticals, Inc., and Pfizer Inc, in an account that is not part of their community property.
William T. Cefalu, MD
Grant/Research Support:	Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc
Consultant:	Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc, Wyeth
Speakers' Bureau:	Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc
Derek LeRoith, MD, PhD
Consultant:	Merck & Co., Inc., Pfizer Inc, sanofi-aventis
Speakers' Bureau:	Merck & Co., Inc., Pfizer Inc, sanofi-aventis
Tulane Faculty Liaison Tina Thethi, MD
Assistant Professor of Medicine, Section of Endocrinology Tulane University Health Sciences Center New Orleans, Louisiana Dr. Thethi has documented that she has no financial relationships to disclose.

E S T I M A T E D   T I M E   T O  C O M P L E T E  A C T I V I T Y
1.75 Hours

R E L E A S E / E X P I R A T I O N  D A T E S
December 13, 2007 – December 13, 2008

D I S C U S S I O N  O F  O F F - L A B E L  U S E S
Because this webcast is meant to educate physicians about what is currently in use and what may be available in the future, there are “off-label” uses discussed in the presentations.

A B O U T  C A D R E
CADRE is a nonprofit organization committed to reducing the devastating complications of type 1 and type 2 diabetes. For information on educational activities offered by CADRE, visit the CADRE Web site at www.cadre-diabetes.org.

H O W  T O  O B T A I N  C R E D I T
Viewers are expected to view and listen to all presentations before applying for CME credit. Please follow these steps in order to receive a CME certificate of credit awarding AMA PRA Category 1 Credit™ for viewing the webcast:

• Read all of the CME information above.
• View and listen to the complete webcast program.
• Click on the link to apply for CME credits.
• Complete and submit (by mail, fax, or e-mail) the Verification of Credit and Program Evaluation Forms (in Microsoft Word).
• Your Record of Credit will be sent to you within 30 days of receipt.

To receive credit, the course must be completed before December 13, 2008.

If you attended the live presentation on June 22, 2007, and received CME credit for this program, you are not eligible for additional credit.

Participation in this activity should be completed in approximately 1.75 hours.

If you have any CME questions regarding this activity, please contact:
Tulane University
1430 Tulane Ave., TB-51
New Orleans, LA 70112-2699
Tel: 504-988-5466 Fax: 504-988-1779
http://www.cme.tulane.edu
cme@tulane.edu

P R I V A C Y  P O L I C Y
It is the policy of Tulane University Health Sciences Center and its Center for Continuing Education (CCE) that personal information for CME activities will be collected only to the extent necessary to provide the service or benefit desired. Only appropriate information will be collected and can be available to be reviewed by the individual providing the information.